LFMD250516C9000
- 0.15
- +0.02+15.38%
LifeMD Newsroom
A Quick Look at Today's Ratings for LifeMD(LFMD.US), With a Forecast Between $8 to $15
H.C. Wainwright Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $14
H.C. Wainwright Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $14
LifeMD Analyst Ratings
Lake Street Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $12
Lake Street Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $12
Lake Street Sticks to Its Buy Rating for LifeMD (LFMD)
KeyBanc Initiates LifeMD(LFMD.US) With Buy Rating, Announces Target Price $7
Freedom Capital Markets Initiates LifeMD(LFMD.US) With Buy Rating, Announces Target Price $13
Mizuho Securities Reaffirms Their Hold Rating on LifeMD (LFMD)
H.C. Wainwright Maintains LifeMD(LFMD.US) With Buy Rating, Raises Target Price to $14
LifeMD Is Maintained at Buy by HC Wainwright & Co.
LifeMD's Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating and Raised Price Target
LifeMD Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on LifeMD, Maintains $15 Price Target
KeyBanc Maintains LifeMD(LFMD.US) With Buy Rating, Raises Target Price to $7.5
Analysts Conflicted on These Healthcare Names: Mind Medicine (MNMD), RAPT Therapeutics (RAPT) and LifeMD (LFMD)
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
Lake Street Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $12